Association of immune checkpoint inhibitor with survival in patients with cancers with protein tyrosine phosphatase receptor T mutation

Clin Transl Med. 2020 Oct;10(6):e214. doi: 10.1002/ctm2.214.

Zifan He¹, Anlin Li^{1

2}, Dagui Lin³, Yang Gu¹, Yongjian Chen⁴, Qiyun Ou¹, Liren Li³, Herui Yao¹, Yunfang Yu¹

¹ Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
² The First Clinical Medical College, Guangdong Medical University, Zhanjiang, China.
³ Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
⁴ Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

No abstract available

Publication types